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Abiraterone and Increased Survival in Metastatic  
Prostate Cancer
To the Editor: De Bono et al. (May 26 issue)1 
report that the CYP17 inhibitor abiraterone in-
creased survival in patients with metastatic cas-
tration-resistant prostate cancer. However, CYP17 
inhibition leads to a corticotropin-induced min-
eralocorticoid excess that needs to be efficiently 
counteracted.2 In this study, such hormone de-
rangement was mitigated but not abolished by 
the concomitant administration of prednisone. A 
greater incidence of hypokalemia and fluid re-
tention was seen in patients receiving abiraterone 
plus prednisone than in those receiving placebo 
plus prednisone, and this may have contributed 
to the greater cardiac toxicity observed. It would 
be interesting to know how the investigators man-
aged these side effects and the results obtained. 
In particular, was the prednisone dose increased? 
Were mineralocorticoid-receptor blockers intro-
duced? Because of its intrinsic mineralocorticoid 
activity,3 prednisone may be not the best drug to 
be used in this context, and the potential intro-
duction of dexamethasone as an alternative should 
be discussed.2 Finally, the authors should discuss 
the utility of monitoring serum corticotropin lev-
els during abiraterone treatment in order to ad-
just the supplementation therapy on an individual 
basis.
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To the Editor: With the approval of cabazitaxel 
as a second-line therapy after the failure of 
docetaxel in patients with metastatic castration-
resistant prostate cancer, it would be interesting 
to know the views of de Bono et al. on possible 
clinical measurements that might help in guid-
ing the choice of cabazitaxel or abiraterone ace-
tate.1 In their study, treatment was continued 
until disease progression on the basis of the 
prostate-specific antigen (PSA) level, radiographic 
imaging, and clinical findings. However, a clari-
fication of whether abiraterone was discontinued 
for isolated PSA progression is necessary. Finally, 
the median progression-free survival (5.6 months) 
was substantially shorter than the median time 
to PSA progression (10.2 months) in the abira-
terone group, which suggests a decoupling of 
PSA changes and antitumor activity. Did patients 
have objective progression in the context of PSA 
responses? Hence, should radiographic assess-
ment be performed more frequently, or is a min-
imum of 12 weeks of therapy warranted before 
objective radiographic assessments in accordance 
with the recommendations of the Prostate Can-
cer Working Group 2? 2
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To the Editor: In their editorial, Antonarakis 
and Eisenberger1 list no fewer than 21 completed 
and ongoing phase 3 trials of new agents in met-
astatic prostate cancer. We are surprised and dis-
appointed at the omission of the Alpharadin in 
Symptomatic, Hormone-Refractory Prostate Can-
cer trial (ALSYMPCA; ClinicalTrials.gov number, 
NCT00699751). Radium-223 is a novel alpha-
pharmaceutical that specifically targets bone 
metastases and has shown excellent efficacy and 
safety in a randomized phase 2 trial.2 The omis-
sion of the ALSYMPCA trial is all the more unfor-
tunate because since the editorial appeared, the 
trial has had a positive interim analysis for the 
overall survival end point. Radium-223 now joins 
a select list of just five drugs that have been 
shown to improve overall survival in patients 
with advanced prostate cancer.
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Dr. de Bono and colleagues reply: In response 
to the comments of Sonpavde: no data are avail-
able at this time to guide the sequencing of treat-
ment for castration-resistant prostate cancer after 
the failure of docetaxel. We envision several sce-
narios: abiraterone administered with cabazitaxel 
from the outset, abiraterone given first, or ca-
baz itaxel delivered first. This raises the key issue: 
Does cross-resistance between abiraterone and 
the taxanes exist? Preclinical data indicate that 
the taxanes have antitumor activity in this dis-
ease by affecting androgen-receptor signaling.1
Studies evaluating the tolerability and efficacy 
of the abiraterone-plus-cabazitaxel combination 
and randomized phase 3 trials evaluating the 
efficacy of different sequencing schedules are 
needed.
Practically, however, the patient’s performance 
status, along with bone marrow and liver func-
tion, can guide further therapy. Moreover, pilot 
data have shown an association between pre-
treatment levels of plasma androgenic steroid 
hormone and ERG rearrangements and the re-
sponse to abiraterone.2,3 Further studies of pa-
tient selection and molecular stratification are 
needed to optimize individual treatment.
Finally, patients were not discontinued from 
the abiraterone 301 trial because of PSA progres-
sion only. Also, progression-free survival was 
defined purely on the basis of radiologic data or 
death; the dichotomy between median time to 
PSA progression and radiologic progression-free 
survival may be due to the censoring of data for 
patients. It is important to note that flares that 
are seen on bone scans and computed tomogra-
phy are common after treatment with abiraterone, 
and apparent worsening shown on these scans 
after treatment can be misleading.4,5
The incidence of toxic effects associated with 
CYP17 blockade by abiraterone acetate in our study 
was low, and such effects were easily managed 
by adequate doses of glucocorticoid or mineralo-
corticoid antagonists. Some steroidal mineralo-
corticoid antagonists, including spironolactone, 
can activate the androgen receptor and should not 
be used in patients with prostate cancer. Most 
patients did not require dose reduction; 3.8% of 
patients receiving abiraterone and 2.8% of those 
receiving placebo required increased doses of 
prednisone or prednisolone. Overall, 1.6% of pa-
tients receiving abiraterone and 1.8% of those 
receiving placebo received the mineralocorticoid-
receptor antagonist eplerenone. However, further 
studies are warranted to evaluate whether differ-
ent regimens (such as low-dose dexamethasone) 
can minimize both mineralocorticoid and iatro-
genic glucocorticoid toxic effects. Dexametha-
sone was used with abiraterone in our trial using 
continuous doses of abiraterone.2
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Table 1. Results of Meta-Analysis of Trials Evaluating Overall Survival in Patients Receiving Gemcitabine-Based Combination Therapy, as 
Compared with Single-Agent Gemcitabine.*
Drug Combined 
with Gemcitabine
Randomized 
Clinical Trials† 
No. of 
Trials
No. of  
Patients
Hazard Ratio
(95% CI) P Value
Absolute 
Difference 
at 1 Yr (%) 
No. Needed 
to Treat‡
Between-Group 
Comparison Heterogeneity
Cisplatin Colucci et al. (2002)
Heinemann et al.
Colucci et al. (2010)
3 702 0.94 (0.76–1.17) 0.61 0.19 NA NA
Oxaliplatin Louvet et al.
Poplin et al.
2 868 0.86 (0.74–0.99) 0.04 0.65 2.6 38–39
Capecitabine Cunningham et al.
Herrmann et al.
2 852 0.86 (0.75–0.99) 0.04 0.94 3.0 33–34
Total 7 2422 0.87 (0.80–0.96) 0.005 0.53 2.3 43–44
* NA denotes not applicable.
† Included in the meta-analysis were the following studies: Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the 
treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the 
Gruppo Oncologia dell’Italia Meridionale. Cancer 2002;94:902-10; Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial 
of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52; Colucci G, 
Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-
line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645-51; Louvet C, Labianca R, Hammel 
P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic can-
cer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16; Poplin E, Feng Y, Berlin J, et al. Phase III, randomized 
study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in pa-
tients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778-85. [Erratum, J Clin 
Oncol 2009;27:5859.]; Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine 
plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-8; Herrmann R, Bodoky G, Ruhstaller T, et al. 
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial 
of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-17.
‡ The number needed to treat refers to the number of patients who would need to be treated with the combination therapy for one patient 
to benefit in terms of outcome.
FOLFIRINOX versus Gemcitabine for Metastatic  
Pancreatic Cancer
To the Editor: Conroy et al. (May 12 issue)1 re-
port that FOLFIRINOX (a combination chemo-
therapy regimen consisting of oxaliplatin, irino-
tecan, fluorouracil, and leucovorin) provided a 
statistically and clinically significant benefit over 
single-agent gemcitabine in patients with ad-
vanced pancreatic cancer. Although the increased 
toxicity associated with this combination therapy 
may temper enthusiasm, this is the first real ad-
vance in such therapy since the introduction of 
gemcitabine. It has been debated whether gem-
citabine-based combination therapies provide any 
additional benefit, and meta-analyses have reached 
conflicting conclusions.2-4 A sensitivity analysis of 
data pooled from seven randomized trials involv-
ing 2422 patients in which single-agent gemcita-
bine was compared with gemcitabine in combi-
nation with cisplatin, oxaliplatin, or capecitabine 
indicates that the use of gemcitabine-based dou-
blets had a clinically negligible, although statisti-
cally significant, absolute survival benefit (Ta-
ble 1). However, power calculations reliably (80% 
power, two-tailed alpha of 0.05) rule out the pos-
sibility that gemcitabine-based doublets could 
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